Results 221 to 230 of about 5,601,796 (250)

Polymer-Enabled Additive Manufacturing for Personalized Drug Delivery and Diagnostic Platforms: Materials, Architectures, Quality Control and Clinical Translation. [PDF]

Polymers (Basel)
Pandian P, Sethuraman V, Shukla AK, Nagappan A.   +3 more
europepmc   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities. [PDF]

Pharmaceutics
Pai VB, Nahata MC.
europepmc   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source

Astaxanthin Delivery Across Administration Routes: Recent Advances to Improve Stability and Bioavailability. [PDF]

Pharmaceutics
Novelli L, Cespi M, Perinelli DR, Bonacucina G.   +3 more
europepmc   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source

The need for patient-centric medicine design: investigating key physical characteristics of oral solid medications to improve acceptance of older patients in Addis Ababa, Ethiopia. [PDF]

PLoS One
Assefa MC, Paulos G, Ejeta F, Borga DK.
europepmc   +1 more source

Colour of medicines and children's acceptability: What children think of the colour of oral dosage forms? [PDF]

Front Drug Deliv
Alessandrini E, Gizurarson S, Walsh J, Turner R, Schaufelberger D, Iurian S, Batchelor H, Klein S, Nafria B, Dicks P, Gaillard S, Franz AR, Albano J, Wisniewski A, Vermehren C, Gade C, Andersen JT, Tuleu C.   +17 more
europepmc   +1 more source

Analysis of Dissolution, Pharmacokinetic, and Bone-Protective Differences Among Calcium Formulations with Different Dosage Forms and Calcium Sources. [PDF]

Pharmaceuticals (Basel)
Wang M, Liu S, Wei G, Wang H, Huang Z, Ding Y, Han G.   +6 more
europepmc   +1 more source

Off-Label Manipulation of Paediatric Medication Remains a Challenge in Clinical Practice: An Observational Study. [PDF]

Acta Paediatr
Hamre Svendsen R, Andersen JKN, Kälvemark Sporrong S, Andersson Y, Tho I.   +4 more
europepmc   +1 more source